PTX3 and metabolic syndrome: Thus, additional follow-up of patients with genetically determined dyslipidemia and CAD is required, with well-planned, continuous, long-term treatment to further investigate the therapeutic potential of lowering PTX3 directly or through gene-silencing treatments.